Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia
Table 3
Bivariate and multivariate logistic regression analyses of time spent within the therapeutic INR range (TTR) among patients taking warfarin in University of Gondar, Northwest Ethiopia, from November 1, 2019, to October 31, 2020 (n = 338).
Variables
TTR
COR (CI)
value
AOR (CI)
value
TTR < 65%
TTR ≥ 65%
Age
<40 years
100
15
1.04 (0.48, 2.27)
0.922
40–60 years
97
13
0.94 (0.42, 2.12)
0.877
>60 years
99
14
1
Gender
Male
103
18
1
Female
193
24
1.41 (0.73, 2.71)
0.310
Marital status
Single
50
11
1
Married
218
28
1.98 (0.51, 7.71)
0.325
Others
27
3
1.15 (0.33, 4.04)
0.825
Monthly income
<1500 birr
157
26
1
1500–3000 birr
77
8
1.28 (0.55, 2.99)
0.563
>3000 birr
62
8
0.81 (0.29, 2.27)
0.682
Educational level
Cannot read and write
61
10
1
Informal education
91
12
1.80 (0.53, 6.12)
0.345
Elementary school
45
6
1.45 (0.44, 4.76)
0.539
Secondary school
54
10
1.47 (0.39, 5.56)
0.573
College and above
44
4
2.04 (0.60, 6.94)
0.255
Residence
Urban
170
23
0.89 (0.47, 1.72)
0.744
Rural
126
19
1
BMI (kg/m2)
<18.5
25
4
1
18.5–24.9
199
30
1.44 (0.39, 5.19)
0.578
≥25
72
8
1.36 (0.59, 3.09)
0.469
Indication for warfarin
Atrial fibrillation
222
30
1
VTE
64
8
0.14 (0.02, 0.99)
0.049
0.56 (0.14, 2.18)
0.404
Others
10
4
0.31 (0.08, 1.23)
0.097
0.43 (0.09, 1.94)
0.271
Dose of warfarin
<5 mg daily
181
18
1
5 mg daily
98
20
0.39 (0.12, 1.32)
0.133
0.40 (0.09, 1.64)
0.282
>5 mg daily
17
4
0.91 (0.28, 2.98)
0.877
0.94 (0.24, 3.74)
0.950
Nonadherence to warfarin
Yes
40
2
1
No
266
30
2.26 (0.52, 9.81)
0.278
Concomitant drugs use
Yes
268
37
1
No
28
5
1,29 (0.47, 3.56)
0.618
Frequency of INR monitoring
Every 2 weeks
28
4
0.68 (0.15, 3.05)
0.613
Every 1 month
249
34
0.65 (0.21, 2.02)
0.455
Every 2 months
19
4
1
Alcohol intake
Yes
54
6
1
No
241
36
1.34 (0.54, 3.34)
0.531
Chronic liver disease
Yes
14
3
0.91 (0.46, 1.80)
0.791
No
122
16
1
Unknown
160
23
1.49 (0.39, 5.59)
0.554
Chronic kidney disease
Yes
25
4
1.32 (0.62, 2.85)
0.473
No
184
28
1
Unknown
87
10
1.39 (0.40, 4.82)
0.602
Heart failure
Yes
130
14
1
No
166
28
0.64 (0.32, 1.26)
0.197
1.70 (0.80, 3.61)
0.168
Hyperthyroidism
Yes
45
6
1
No
251
36
0.93 (0.37, 2.33)
0.877
BMI, body mass index; VTE, venous thromboembolism; concomitant drugs use included antiplatelets, statins, antihypertensives, antithyroid drugs, and antiretroviral drugs.